July 29, 2019 | Letisia Marquez
City of Hope has been named the best cancer hospital in the West by U.S. News & World Report’s 2019-20 Best Hospitals: Specialty Ranking. This marks the 13th consecutive year it has been distinguished as one of the nation’s elite cancer hospitals.
City of Hope Physicians Announce New CAR T Breakthroughs at Annual ASH Meeting
December 14, 2017 | Letisia Marquez
New blood cancer breakthroughs – including several involving CAR T cell therapy – were announced by City of Hope physicians at the American Society of Hematology (ASH) annual meeting in Atlanta.
Combination Immunotherapy Shown to Be Effective Initial Treatment for Relapsed or Refractory Hodgkin Lymphoma
December 11, 2017 | Katie Neith
Researchers led by Alex Herrera, M.D. have found that a combination of two immunotherapy drugs may be a more tolerable way for patients to fight the disease before a transplant.
Trial Results Point to Promising Treatments for Hodgkin Lymphoma Patients
January 9, 2017 | Abe Rosenberg
Everything changed when Hodgkin lymphoma patient Lowell Winer joined a phase 2 clinical trial examining the effectiveness of brentuximab vedotin (BV) after a failed transplant. The BV worked immediately, achieving a complete remission which, year after year, proved to be durable beyond anyone's expectations.
When Hodgkin Lymphoma returns, a new drug may offer hope
August 16, 2016 | Letisia Marquez
Patients whose Hodgkin lymphoma has returned after a stem cell transplant have few treatment options available but a new drug tested at City of Hope may change that. ABC-7 in Los Angeles featured research by Robert Chen, M.D., on the use of the new medication – brentuximab vedotin (BV) – by these patients.
Research suggests brentuximab vedotin potentially curative in some Hodgkin lymphoma patients with limited treatment options
July 18, 2016 | City of Hope
Study, published in Blood, reports on five-year survival data, suggests targeted therapy should be standard of care for patients with relapsed or treatment-resistant Hodgkin lymphoma.